RE: So-called expert analysis12 Jul 2016 10:30
Haha,
Yes, look at all those Pharma companies valued at £20m-£100m at the moment without a deal.
OXP was valued at £10m at the same stage as N4 are now. Then NT licensed the platforms, received the royalties and took the company to £100m+ within 3 years
And looking to do the exact same thing here again - but better.
More varied technology, bigger markets, bigger appeal, bigger profits.
NT targeting £500m+ business.